Get the Stockscreener App
6.805
0.81%
0.055
After Hours:
6.68
-0.125
-1.84%
Satellos Bioscience Inc stock is traded at $6.805, with a volume of 13,826.
It is up +0.81% in the last 24 hours and down -2.51% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$6.75
Open:
$6.85
24h Volume:
13,826
Relative Volume:
0.19
Market Cap:
$141.76M
Revenue:
-
Net Income/Loss:
$-24.87M
P/E Ratio:
-5.1557
EPS:
-1.3199
Net Cash Flow:
$-23.65M
1W Performance:
-2.65%
1M Performance:
-2.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.67
$7.0012
1-Week Range:
$6.67
$7.46
52-Week Range:
$5.50
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
6.805 | 140.61M | 0 | -24.87M | -23.65M | -1.3199 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience (MSLE) Slides 5.5% as Biotech Sector Headwinds Weigh on SentimentHidden Order - Newser
Satellos Bioscience Q1 2026 Earnings: Narrower Loss Reported, Stock Slips on Lack of Revenue Progress - Newser
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Narrower-Than-Expected Loss Marks Progress Amid Pre-Revenue StageCEO Earnings Statement - Newser
MSLE Stock Price, Quote & Chart | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
CCORF Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $13.81 - Moomoo
Satellos Bioscience Sets June 17, 2026 Virtual Annual Shareholder Meeting - TipRanks
Virtual AGM, board elections and pay disclosure at Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
MSLE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Satellos Bioscience Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Satellos Bioscience (MSLE) Q1 2026 Earnings: EPS $-0.53 Beats EstimatesHigh Attention Stocks - newser.com
Satellos Bioscience (TSX:MSCL) Extends Cash Runway Confidence - Kalkine Media
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $11 - Moomoo
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate - Yahoo Finance
Stocks In Play - Baystreet.ca
Satellos Bioscience (MSLE) insiders report 1.14M shares, 7.35% stake - Stock Titan
Positive Developments for Satellos (MSLE) in Q1 2026 - GuruFocus
Satellos Bioscience Inc. - Baystreet.ca
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress - Investing News Network
Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis - marketscreener.com
Satellos Bioscience Posts Wider Q1 2026 Loss but Strengthens Balance Sheet - TipRanks
Satellos Bioscience: Q1 Earnings Snapshot - marketscreener.com
Satellos Bioscience (NASDAQ: MSLE) raises $57M and advances Duchenne trials - Stock Titan
MSLE Price Today: Satellos Bioscience Inc. Stock Price, Quote & Chart | MEXC - MEXC
Qiming reports 1.725M Satellos shares; MSLE ownership disclosure - Stock Titan
Number of shareholders of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
What Satellos Bioscience (MSLE) is doing that separates it from the herd (+0.13%) 2026-05-11Alpha Picks - newser.com
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08Real-time Trade Ideas - Newser
MSLE Satellos Bioscience stock rallies 7.7% despite 941% earnings miss, zero revenue as investors eye biotech potential.Social Flow Trades - Newser
Certain Stock Options of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026. - marketscreener.com
Satellos Bioscience Inc expected to post a loss of 69 cents a shareEarnings Preview - TradingView
Guggenheim Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $23 - Moomoo
Guggenheim Initiates Satellos Bioscience at Buy With CA$31.43 Price Target - Moomoo
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit - TMX Newsfile
Satellos Bioscience (NASDAQ:MSLE) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Satellos prices $50M public offering - MSN
MSLE Satellos Bioscience Inc. reports far wider than expected Q4 2025 loss while its shares post modest gains amid positive investor sentiment.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Satellos Bioscience (MSLE) Stock: Portfolio Allocation (Bearish Sentiment) 2026-04-20Community Chart Signals - Xã Châu Thành
MSLE : Satellos Bioscience Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
MSLE: Satellos Bioscience Inc.Insider Transations - Zacks Investment Research
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference - Investing News Network
Satellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor Conference - TipRanks
Satellos Bioscience (NASDAQ: MSLE) plans Bloom Burton investor conference presentation - Stock Titan
Satellos Bioscience (NASDAQ:MSLE) Coverage Initiated by Analysts at Leerink Partners - Defense World
Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners - MarketBeat
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):